Evidence map›Paper›PMID 30958843›Full record

ArticlePloS one2019

CD46 knock-out using CRISPR/Cas9 editing of hTERT immortalized human cells modulates complement activation.

Matthias Wieser, Teresa Francisci, Daniel Lackner, Tilmann Buerckstuemmer, Kamilla Wasner, Wolf Eilenberg, Anton Stift, Markus Wahrmann, Georg A Böhmig, Johannes Grillari and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Matthias WieserEvercyte GmbH, Vienna, Austria.
Teresa FrancisciEvercyte GmbH, Vienna, Austria.
Daniel LacknerHorizon Genomics GmbH, Vienna, Austria.
Tilmann BuerckstuemmerHorizon Genomics GmbH, Vienna, Austria.
Kamilla WasnerDepartment of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.
Wolf EilenbergDepartment of Surgery, Medical University of Vienna, Vienna, Austria.
Anton StiftDepartment of Surgery, Medical University of Vienna, Vienna, Austria.
Markus WahrmannDepartment of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-1301-8694
Georg A BöhmigDepartment of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.
Johannes GrillariEvercyte GmbH, Vienna, Austria.
Regina Grillari-VoglauerEvercyte GmbH, Vienna, Austria.
Medical University of Vienna · ATEvercyte (Austria) · ATChristian Doppler Laboratory for Thermoelectricity · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The kidney is especially sensitive to diseases associated with overactivation of the complement system. While most of these diseases affect kidney glomeruli and the microvasculature, there is also evidence for tubulointerstitial deposition of complement factors. Complement inactivating factors on cell membranes comprise CD55, CD59 and CD46, which is also termed membrane cofactor protein (MCP). CD46 has been described as localized to glomeruli, but especially also to proximal tubular epithelial cells (RPTECs). However, human cell culture models to assess CD46 function on RPTECs are still missing. Therefore, we here performed gene editing of RPTEC/TERT1 cells generating a monoclonal CD46-/- cell line that did not show changes of the primary cell like characteristics. In addition, factor I and CD46-mediated cleavage of C4b into soluble C4c and membrane deposited C4d was clearly reduced in the knock-out cell line as compared to the maternal cells. Thus, human CD46-/- proximal tubular epithelial cells will be of interest to dissect the roles of the epithelium and the kidney in various complement activation mediated tubulointerstitial pathologies or in studying CD46 mediated uropathogenic internalization of bacteria. In addition, this gives proof-of-principle, that telomerized cells can be used in the generation of knock-out, knock-in or any kind of reporter cell lines without losing the primary cell characteristics of the maternal cells.

Indexed as

Complement ActivationCRISPR-Cas SystemsGene Knockout TechniquesCell LineComplement C4Complement C4bEpithelial Cellsgamma-GlutamyltransferaseGene EditingHumansKidney TubulesMembrane Cofactor ProteinTelomeraseTelomereCD46 protein, humanComplement C4Complement C4bgamma-GlutamyltransferaseMembrane Cofactor ProteinTelomeraseTERT protein, human

Identifiers

PMID30958843
PMCPMC6453361
OpenAlexW2937216372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.